The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.
Francisco Emilio Vera-Badillo
No relevant relationships to disclose
Raya Leibowitz-Amit
No relevant relationships to disclose
Arnoud Templeton
Honoraria - Astellas Pharma
Jo-An Seah
No relevant relationships to disclose
Srikala S. Sridhar
No relevant relationships to disclose
Jennifer J. Knox
No relevant relationships to disclose
Ian Tannock
No relevant relationships to disclose
Anthony Michael Joshua
No relevant relationships to disclose